Literature DB >> 9548514

Induction of high affinity fibroblast growth factor receptor expression and proliferation in human endothelial cells by anti-HLA antibodies: a possible mechanism for transplant atherosclerosis.

P E Harris1, H Bian, E F Reed.   

Abstract

The major limitation to long term survival of organ allografts is chronic rejection, which is manifested as atherosclerosis of the vessels of the transplanted organ. There is a significant association between transplant atherosclerosis and the development of Abs to the disparate HLA Ags present on the graft vasculature. We have investigated the effect of anti-HLA Abs on endothelial cells (EC) and smooth muscle cells cultured in vitro. Ab ligation of class I molecules on ECs results in increased high affinity fibroblast growth factor receptor mRNA expression, and enhanced basic fibroblast growth factor ligand binding. Ab binding to class I molecules on EC and smooth muscle cells is also accompanied by augmented cell proliferation. These results suggest that the intimal thickening observed in transplant atherosclerosis is the result of the proliferative effects of anti-HLA Abs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9548514

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  19 in total

1.  A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody.

Authors:  T Hirohashi; C M Chase; P Della Pelle; D Sebastian; A Alessandrini; J C Madsen; P S Russell; R B Colvin
Journal:  Am J Transplant       Date:  2011-11-09       Impact factor: 8.086

2.  HLA class I molecules partner with integrin β4 to stimulate endothelial cell proliferation and migration.

Authors:  Xiaohai Zhang; Enrique Rozengurt; Elaine F Reed
Journal:  Sci Signal       Date:  2010-11-23       Impact factor: 8.192

3.  Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern.

Authors:  Eduardo Reyes-Vargas; Igor Y Pavlov; Thomas B Martins; Jason J Schwartz; Harry R Hill; Julio C Delgado
Journal:  J Clin Lab Anal       Date:  2009       Impact factor: 2.352

Review 4.  Sensitive solid-phase detection of donor-specific antibodies as an aid highly relevant to improving allograft outcomes.

Authors:  Gerald Schlaf; Beatrix Pollok-Kopp; Wolfgang W Altermann
Journal:  Mol Diagn Ther       Date:  2014-04       Impact factor: 4.074

Review 5.  The link between major histocompatibility complex antibodies and cell proliferation.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Transplant Rev (Orlando)       Date:  2011-07-30       Impact factor: 3.943

6.  De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II.

Authors:  Zhongping Xu; Deepak K Nayak; Nicholas Benshoff; Ramsey Hachem; Andrew E Gelman; Thalachallour Mohanakumar
Journal:  J Immunol       Date:  2015-05-04       Impact factor: 5.422

7.  Everolimus inhibits anti-HLA I antibody-mediated endothelial cell signaling, migration and proliferation more potently than sirolimus.

Authors:  Y-P Jin; N M Valenzuela; M E Ziegler; E Rozengurt; E F Reed
Journal:  Am J Transplant       Date:  2014-03-01       Impact factor: 8.086

8.  Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by Anti-MHC I antibodies.

Authors:  Haseeb Ilias Basha; Sabarinathan Ramachandran; Venkataswarup Tiriveedhi; Masashi Takenaka; Vijay Subramanian; Dilip S Nath; Nicholas Benshoff; G Alec Patterson; Thalachallour Mohanakumar
Journal:  Transplantation       Date:  2013-01-27       Impact factor: 4.939

Review 9.  Mechanism of cellular rejection in transplantation.

Authors:  Elizabeth Ingulli
Journal:  Pediatr Nephrol       Date:  2010-01       Impact factor: 3.714

10.  Report from a consensus conference on the sensitized patient awaiting heart transplantation.

Authors:  Jon Kobashigawa; Mandeep Mehra; Lori West; Ronald Kerman; James George; Marlene Rose; Adriana Zeevi; Nancy Reinsmoen; Jignesh Patel; Elaine F Reed
Journal:  J Heart Lung Transplant       Date:  2009-03       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.